Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

NCT02168101 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: MLN9708

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]